Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report
Authors
Keywords
-
Journal
NEUROSURGERY
Volume Publish Ahead of Print, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-05-12
DOI
10.1227/neu.0000000000002024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020
- (2020) Jacqueline Trouillas et al. Cancers
- Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
- (2020) Camille Duhamel et al. Journal of Personalized Medicine
- Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: a new emerging treatment?
- (2020) Bastiaan Sol et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
- (2020) Nazanin Majd et al. Journal for ImmunoTherapy of Cancer
- The Treatment of Refractory Pituitary Adenomas
- (2019) Congxin Dai et al. Frontiers in Endocrinology
- Treatment and long-term outcomes in pituitary carcinoma: a cohort study
- (2019) Fernando Santos-Pinheiro et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab
- (2019) Mario Caccese et al. ANTI-CANCER DRUGS
- Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
- (2019) Jingli Lu et al. Cancer Medicine
- Definition and diagnosis of aggressive pituitary tumors
- (2019) Leandro Kasuki et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- (2018) Xiaolei Li et al. Cellular & Molecular Immunology
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR–Chk1 Pathway
- (2018) Shinsuke Uraki et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
- (2011) Ann I. McCormack et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
- (2011) Mineko Murakami et al. NEUROSURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now